0001209191-20-008727.txt : 20200212
0001209191-20-008727.hdr.sgml : 20200212
20200212162003
ACCESSION NUMBER: 0001209191-20-008727
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200210
FILED AS OF DATE: 20200212
DATE AS OF CHANGE: 20200212
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kauffman Michael
CENTRAL INDEX KEY: 0001364719
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 20604376
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS INC.
STREET 2: 85 WELLS AVENUE, SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-658-0600
MAIL ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-10
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001364719
Kauffman Michael
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON
MA
02459
1
1
0
0
Chief Executive Officer
Common Stock
2020-02-11
4
M
0
10000
4.752
A
552139
D
Common Stock
2020-02-11
4
S
0
10000
17.4294
D
542139
D
Common Stock
2020-02-10
4
M
0
10000
4.752
A
753506
I
By Spouse
Common Stock
2020-02-10
4
S
0
10000
16.9327
D
743506
I
By Spouse
Stock Option (right to buy)
4.752
2020-02-11
4
M
0
10000
0.00
D
2023-09-02
Common Stock
10000
376061
D
Stock Option (right to buy)
4.752
2020-02-10
4
M
0
10000
0.00
D
2023-09-02
Common Stock
10000
420303
I
By Spouse
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $17.215 to $17.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $16.793 to $17.21, inclusive. The spouse of the reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.
/s/Christopher B. Primiano, Attorney-in-Fact for Michael Kauffman
2020-02-12